Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019912 | 0.87 | NOD1 (0.47) | GLP1RNOD1TLR2CAPN1MEN1 | |
| SCHEMBL30019872 | 0.86 | NOD1 (0.47) | GLP1RNOD1CAPN1MEN1ALDH1A1 | |
| SCHEMBL30020812 | 0.82 | GLP1R (0.46) | GLP1RNOD1CAPN1SIRT2 | |
| SCHEMBL24235778 | 0.80 | GLP1R (0.43) | GLP1RNOD1CAPN1KMT2A | |
| SCHEMBL30020211 | 0.78 | DPP7 (0.55) | NOD1TLR2 | |
| SCHEMBL30019732 | 0.78 | NOD1 (0.50) | GLP1RNOD1TLR2CAPN1SIRT2 | |
| SCHEMBL30019660 | 0.77 | NOD1 (0.50) | GLP1RNOD1TLR2CAPN1SIRT2 | |
| SCHEMBL27248175 | 0.77 | KMT2A (0.49) | TLR2SIRT2MEN1ALDH1A1HPGD | |
| SCHEMBL27148691 | 0.76 | NOD1 (0.49) | GLP1RNOD1TLR2CAPN1SIRT2 | |
| SCHEMBL30020169 | 0.76 | NOD1 (0.49) | GLP1RNOD1TLR2CAPN1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199663-A1 | Cyclopolyphosphazenes, Related Methods of Preparation and Methods of Use | UNITED STATES DEPARTMENT OF ENERGY | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199663-A1 | Cyclopolyphosphazenes, Related Methods of Preparation and Methods of Use | PHOSPHO1, TOP2B, TOP2A | GLP1R 4755/4885NOD1 514/4885TLR2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.